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Abstract
Despite the advances in diagnosis and treatment of oral squamous cell carcinoma (OSCC), mortality and morbidity rates
have not improved over the past decade. A major drawback in diagnosis and treatment of OSCC is the lack of knowledge
relating to how genetic instability in oral cancer genomes affects oral carcinogenesis. Hence, the key aim of this study was
to identify copy number alterations (CNAs) that may be cancer associated in OSCC using high-resolution array comparative
genomic hybridization (aCGH). To our knowledge this is the first study to use ultra-high density aCGH microarrays to profile
a large number of OSCC genomes (n = 46). The most frequently amplified CNAs were located on chromosome 11q11(52%),
2p22.3(52%), 1q21.3–q22(54%), 6p21.32(59%), 20p13(61%), 7q34(52% and 72%),8p11.23–p11.22(80%), 8q11.1–q24.4(54%),
9q13–q34.3(54%), 11q23.3–q25(57%); 14q21.3–q31.1(54%); 14q31.3–q32.33(57%), 20p13–p12.3(54%) and 20q11.21–
q13.33(52%). The most frequently deleted chromosome region was located on 3q26.1 (54%). In order to verify the CNAs
from aCGH using quantitative polymerase chain reaction (qPCR), the three top most amplified regions and their associated
genes, namely ADAM5P (8p11.23–p11.22), MGAM (7q34) and SIRPB1 (20p13.1), were selected in this study. The ADAM5P
locus was found to be amplified in 39 samples and deleted in one; MGAM (24 amplifications and 3 deletions); and SIRPB1
(12 amplifications, others undetermined). On the basis of putative cancer-related annotations, two genes, namely ADAM
metallopeptidase domain 9 (ADAM9) and maltase-glucoamylase alpha-glucosidase (MGAM), that mapped to CNA regions
were selected for further evaluation of their mRNA expression using reverse transcriptase qPCR. The over-expression of
MGAM was confirmed with a 6.6 fold increase in expression at the mRNA level whereas the fold change in ADAM9
demonstrated a 1.6 fold increase. This study has identified significant regions in the OSCC genome that were amplified and
resulted in consequent over-expression of the MGAM and ADAM9 genes that may be utilized as biological markers for
OSCC.
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Introduction
Oral squamous cell carcinoma (OSCC) is one of the major
causes of cancer-related mortality with an estimation of more than
275,000 new cases and over 120,000 deaths per year [1]. Despite
numerous advances in diagnosis and treatment of oral cancer,
mortality and morbidity rates for OSCC are exceedingly high. A
major drawback in diagnosis and treatment of OSCC is the lack of
detailed understanding of the role of genetic instability in oral
carcinogenesis [2,3].
Genomic re-organizations play an important role in the
pathogenesis of cancer. A successive process of acquired genetic
and epigenetic alterations from a single precursor cell is one of the
hallmarks in tumour development. Changes in copy number
through non-homologous recombination events result in translo-
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cations, insertions or deletions due to re-assortment of exons
between different genes [4,5] which increases the probability of
acquisition of new domains for proteins, fusion transcripts resulting
in potentially new or modified protein functions [6]. Other specific
structural alterations can also result in activation of oncogenes or
inactivation of tumour suppressor genes [7]. This has been
identified in numerous types of lymphomas, leukemias and solid
tumors [7]. Recently, large-scale genomics studies have identified
ubiquitous prevalence of deletions and amplifications in various
cancer genomes [8]. These are mostly the result of the extensive
genomic re-organisation that occurs during tumorigenesis. Iden-
tifying CNAs and how they may be implicated in OSCC is the key
objective of this study.
Recently, array comparative genomic hybridization (aCGH) has
been utilized as a first tier diagnostic tool for genomic profiling to
investigate copy number alterations of various genetic diseases
such as autism, multiple congenital anomalies and developmental
delay [9]. The application of aCGH for identifying DNA copy
number ‘‘signatures’’ or profiling has been carried out in OSCC
studies [3]. Although, previous studies in OSCC have used aCGH,
they only used low-resolution BAC clone aCGH or low-density
oligonucleotide aCGH (4644 k and 16105 k oligonucleotide
based aCGH). As further clarification, these technologies are not
able to detect micro-genomic amplications and deletions (below
30 kb) that could be missed on a targeted BAC clone [10]. In
contrast, our usage of ultra-dense (1 million probe) aCGH
technology has a density that is at least 10-fold higher than
previous studies, enabling detailed information even down to
individual exons [11]. Hence, the key aim of this study was to
identify CNAs in OSCC using ultra-dense, high-resolution aCGH.
To identify the specific genes within the candidate genomic
regions, an independent method of copy number determination by
qPCR was used in an additional independent set of OSCC tumor
samples. Selected amplified genes and their mRNA expression
were determined using reverse transcriptase quantitative PCR
(RT-qPCR) in the CNAs regions.
Materials and Methods
Tumor Samples
Forty-six OSCC frozen tissues were included for the genome
wide screening study using aCGH. In order to validate the CNAs
from aCGH, 48 OSCC samples (12 OSCC samples overlapped
with aCGH samples and an independent set of 36 OSCC samples)
were used. For mRNA expression quantitation study using RT-
qPCR, 30 OSCC (11 OSCC samples overlapped with aCGH
samples and an independent set of 11 OSCC with 4 normal oral
mucosal from non-cancer patients) were employed in this study.
All fresh frozen OSCC tissues and the associated socio-
demographic and clinico-pathological data including age, sex,
ethnicity, and site of lesion were obtained from the Malaysian Oral
Cancer Database and Tissues Bank System (MOCDTBS)
coordinated by the Oral Cancer Research and Coordinating
Centre, University of Malaya [12]. The site of lesion of the OSCC
is classified according to the anatomical subsites of the Interna-
tional Classification of Disease (ICD-10), a coding system that was
developed by World Health Organization (WHO) [13]. Details of
the socio-demographical and clinico-pathological data of this study
cohort are summarized in Table 1. Written informed consent was
obtained before patients were recruited and specimens were
collected, stored and later use for in this study. This study was
approved by the Medical Ethics Committee (MEC), Faculty of
Dentistry, University of Malaya with the MEC code no: DF0306/
001/(L).
DNA and RNA Extraction
All tumor tissues were surgical excision specimens and
immediately snapped frozen in liquid nitrogen. The normal tissues
were obtained from the excessive flap during minor surgical of the
impacted wisdom tooth. The fresh snapped frozen tumor tissues
were cryo-sectioned and stained with haematoxylin and eosin
(H&E) for histological assessment by oral pathologists (TG and
RBZ). After histological confirmation those samples that had a
tumor cell content greater than 70%, were further cryo-sectioned
and were used directly for DNA and RNA extraction from the
whole tissue using DNEasy Blood & Tissue Kit (Qiagen, GmBH
Germany) and RNeasy micro kit (Qiagen, Hilden, Germany),
respectively, according to the manufacturer’s instructions. The
quality (A260/A280, A260/230) and concentration of the gDNA
(ng/ml) was determined using the Nanodrop spectrophotometer
ND-2000 (NanoDrop Technologies, Wilmington, DE, USA). The
integrity of RNA was assessed using the Agilent Bioanalyzer-2100
(Agilent, Palo Alto, CA, USA) and only samples with RNA
integrity number (RIN) more than 6 was included used for cDNA
synthesis that was subsequently used for quantitative PCR (qPCR)
analyses.
Array CGH
Array-CGH was carried out using the SurePrint G3 Human
CGH 161 M array (Agilent Technologies, Santa Clara, CA,
USA) for genome wide survey according to the manufacturer’s
protocol by Oxford Gene Technology as described previously
[14]. The array slides used were oligonucleotide-based micro-
arrays which containing 974,016 probes that enable molecular
profiling of genomic imbalances with 2.1 kb average resolution.
The length of each probe was 60-mer and covers both non-coding
and coding regions of the human genome. Briefly, for each
experiment, a total of 1.5mg gDNA of patient sample and 1.5mg
sex matched reference blood gDNA (Promega, Madison, WI) were
labelled with fluorescence Cy3 and Cy5 respectively using the
CytoSure Genomic DNA labelling kit (Oxford Gene Technology,
UK). The probes were purified using Microcon Centrifugation
Filters, Ultracel YM-30 (Millipore, Billerica, MA, USA) and mixed
together following denaturation and pre-annealing with 50mg of
human Cot-1 DNA (Invitrogen, California). The mixture was then
hybridized to the array slide, where hybridization was performed
at a constant rotation of 20 rpm at 65uC for 40 hours. After
hybridization, slides were washed with Agilent wash buffer 1 and 2
according to the manufacturer’s protocol. Slides were then
scanned immediately using Agilent Microarray Scanner (Agilent
Technologies, USA). The data were extracted from scanned
images using Feature Extraction software, version 10.7.3.1 (Agilent
Technologies, USA). Normalisation was applied using the software
to reduce the inconsistencies and dye incorporation bias. The data
was segmented using a modified Circular Binary Segmentation
(CBS) algorithm [15]. Genomic aberrations were identified by
applying a threshold log2 ratio value of 0.3 for gains and 0.6 for
losses. This ratio was taken because a heterozygous loss of
chromosomal material will result in a theoretical ratio of 2:1, while
a single amplification will give a ratio of 3:2. In order to consider a
segment as an aberration, a minimum of 10 probes were required
in that segment. CNAs were reported in accordance to the human
genome sequence assembly Build 36, Hg 18 (www.ncbi.nlm.nih.
gov). CNAs were analysed using the population analysis feature in
the Cytosure software (Oxford Gene Technology, Oxford, UK).
All statistical analyses were performed using the SPSS statistical
package (SPSS version 12.0, Chicago, IL) where p values ,0.05
was considered significant.
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Copy Number Analysis by the TaqMan PCR Assay
Copy number analysis of ADAM5P, MGAM and SIRBP1 were
performed for tumor DNA, which comprised of an independent
set of 36 OSCC and 12 OSCC samples that overlapped with
aCGH samples. The analysis was done and according to the
manufacturer’s instructions and was processed in an ABI 7500
Fast Real Time PCR System (Applied Biosystems, Foster City,
CA, USA). The gDNA from a healthy volunteer served as
calibrator control for the analysis. Each DNA sample was analysed
in quadruplicate by duplex Taqman real-time polymerase chain
reaction assays. Three assays were selected for copy number
analysis, which were ADAM5P (Hs03268783_cn), MGAM
(Hs04340413_cn) and SIRPB1 (Hs04057639_cn). The reaction
mixtures (20ml) used for amplification were 4ml of genomic
DNA(5 ng/ml), 10ml of 26 TaqManH Genotyping Master Mix
(Applied Biosystems, Foster City, CA, USA), 1 ml of 206Taqman
Copy number assay, 1 ml of 206Taqman copy number reference
assay (RNAse P) and 4 ml of nuclease free water. PCR cycling
conditions were as described in the manufacturer’s instructions.
The gene copy number per diploid genome was calculated using
the equation 26 (22DDCt), comparative CT (DDCT) relative
quantitation method [16]. For the copy number calculation, the
mean of quadruplicate were used for the target assay. For the
reference assay, RNase P, a reference of known copy number (copy
number = 2) with a calibrator sample for each target gene was
taken. RNase P gene is known to exist only in two copies in a
diploid genome. The relative quantity calculated was multiply by a
base copy number of 2 to derive the copy number value. For a
copy number which less than the 1 would be considered as
deletion with one copy number and a copy number more than 2 as
amplification [17,18].
mRNA Expression of ADAM9 and MGAM by RT-qPCR
Nineteen out of 46 samples used in aCGH study were combined
with an independent set of 11 OSCC and 4 normal oral mucosal
frozen tissues from non-cancer patients for RT-qPCR analysis.
This was used to quantify mRNA expression of ADAM9 (ADAM
metallopeptidase domain 9) and MGAM (maltase-glucoamylase
alpha-glucosidase). Total RNA was reverse transcribed using the
High Capacity cDNA reverse transcription kit (Applied Biosys-
tems, Foster City, CA, USA). qPCR reactions were performed in
triplicates on a 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). The TaqMan Gene Expres-
sion Assay (Applied Biosystems, Foster City, CA, USA) was
performed for 2 genes; ADAM9 (Hs00177638_m1) and MGAM
(Hs01090216_m1). All qPCRs were carried out according to the
manufacturer’s protocol (Applied Biosystems, Foster City, CA,
USA). The relative quantification/fold change (RQ) of all genes
was calculated using the 22DDCT method using 7500 Fast System
SDS Software 1.3.1 (Applied Biosystems, Foster City, CA, USA).
The housekeeping gene (GAPDH) was used as an endogenous
control, while the cDNA from normal oral mucosa tissue (RQ = 1)
was utilized to normalise the test samples (OSCC) and any fold
change from OSCC with higher than 1 was considered over-
expressed. The Mann-Whitney U test was used to compare
ADAM9 and MGAM mRNA expression level in tumor and
normal tissues. All statistical analyses were performed using the
SPSS statistical package (SPSS version 12.0, Chicago, IL) where p
values ,0.05 was considered significant.
Results
Copy Number Alterations
Genome wide analysis using aCGH identified 47 genomic
regions in the 46 OSCC cancer genome samples. Filtering was
done on the basis of the log ratio and probe incidence described
above. Comparison with a list of 38 previously identified and
published CNAs in OSCC [19], indicated a concordance of at
least 25.5%. The concordance number is ambigous as previous
studies have used methods with a resolution that is at least ten-fold
lower. Hence likely to under or over report CNAs and their
positions. A particular feature of the results was the heterogeneity
of the samples. Exactly 1/3 of the CNAs were present in a quarter
of all samples. Whereas only 16 out of 47 CNAs were present in
more than half of the samples (n = 46 OSCC). The top most
amplified regions were on chromosome 8p11.23–p11.22 (n = 37,
80%), 7q34 (n = 24, 52%; n = 34, 74%), 20p13 (n = 28, 61%);
6p21.32 (n = 27, 59%), 1q21.3–q22 (n = 25, 54%), 11q11 (n = 24,
52%) 2p22.3 (n = 24, 52%), 8q11.1–q24.4 (n = 25, 54%), 9q13–
q34.3 (n = 25, 54%), 11q23.3–q25 (n = 26, 57%); 14q21.3–q31.1
Table 1. Socio-demographic and clinic-pathologic parameters of 46 OSCC patients.
Sociodemographic Parameters No. of patients n =46 (%)
Gender Male 18 (39.1%)
Female 28 (60.9%)
Ethnicity Malay 12 (26%)
Chinese 9 (19.6%)
Indian 21 (45.7)
Others 4 (8.7%)
Risk Habits Smoking 12 (26%)
Drinking Alcohol 12 (26%)
Betel Quid Chewing 22 (48%)
Clinico-pathologic Parameters
Subsites Tongue 20 (43.5%)
Buccal Mucosa 17 (37%)
Gum 7 (15.2%)
Floor of Mouth 2 (4.3%)
doi:10.1371/journal.pone.0054705.t001
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(n = 25, 54%); 14q31.3–q32.33 (n = 26, 57%), 20p13–p12.3
(n = 25, 54%) and 20q11.21–q13.33 (n = 24, 52%) whereas the
deleted region was 3q26.1 (n = 25, 54%). The percentages in
parentheses indicate the frequency of each event. The most
frequently amplified region, 8p11.23–p11.22 contained several
ADAM family genes (ADAM9, ADAM5P and ADAM32).
Interestingly, almost the entire p-arm of chromosome 8 was
amplified (Figure 1). The second most frequently amplified CNA,
which is located on chromosome 7q34 (Figure 2) contains the
MGAM gene. In contrast to the ADAM9 amplification, the
MGAM genomic amplification is tightly positioned only at the
gene locus. The detailed list of candidate gene(s) for all the
chromosomal aberrations is shown in File S1. The top most
17 CNAs regions were also illustrated in Figure 3. All the CNAs
showed no significant correlation with socio-demographical and
clinic-pathological parameters.
Taqman Copy Number Assay of ADAM5P, MGAM and
SIRPB1
Top three most amplified gene(s) (ADAM5P, MGAM and
SIRPB1) were validated using copy number assay analysis with
48 OSCC samples which comprising of 12 OSCC which over-
lapped with aCGH samples and an independent sample set of
36 OSCC samples. The amplification of the selected genes
identified from aCGH and qPCR were illustrated in Figure 4.
The amplification of ADAM5P were almost similar between
aCGH and qPCR validation with 80% (37/46 OSCC samples)
and 81.25% (39/48 OSCC samples), respectively. Similarly, the
amplification detected for MGAM gene were 74% (37/46 OSCC
samples) in aCGH and 50% (24/48 OSCC samples) in qPCR
validation. However, for SIRPB1, a variation was observed from
aCGH and qPCR validation with 61% (28/46 OSCC samples)
and 25% (12/48 OSCC samples) respectively.
mRNA Expression of MGAM and ADAM9
Both the MGAM and ADAM9 genes were singled out for
further evaluation to confirm the genomic copy number changes
and potential effects on gene expression. ADAM 9 was chosen due
to its gene annotation, suggesting a high probability of involve-
ment in tumorigenesis [20,21]. Similarly, the MGAM gene has
been reported to be amplified in gastric cancer [22]. In this study,
qPCR analyses demonstrated that MGAM was over expressed in
29/30 OSCCs with a fold change of 6.6 (p = 0.001) whereas
ADAM9 was over expressed in 23/30 OSCCs with a fold change
of 1.51 (p = 0.093; Figure 5).
Discussion
In this study, genome wide profiling was carried out using ultra-
high-resolution aCGH to determine the genomic aberrations in a
total of 46 OSCC samples. To the best of our knowledge, this is
the first attempt to use ultra-dense aCGH technology for
discovering CNAs within a large cohort of OSCC samples. As a
result it is possible to identify CNAs down to a resolution of
approximately 3 kb. This compares with the previous highest
resolution study that used 105,000 probes [19]. Given the
quantum level differential between this study and previous studies,
concordance analysis in terms of CNA incidence, position and
degree is challenging. However a broad meta-analysis of 38
previously published CNAs did present a good level of concor-
dance at CNA level (25%), albeit with a high degree of
heterogeneity in samples. This was particularly in relation to
large CNAs such as CNAs as the following positions: 3p26.3-p11.2
(Deletion), 3q24-q29 (Amplification), 5p15.33-p11 (Amplification),
7p22.3-p11.1 (Amplification), 8p23.3-p11.1 (Deletion), 8q11.1-
q24.4 (Amplification). These had been reported as arm level CNAs
in previous studies, whereas we were able to identify intra-CNA
focal, gains and losses, due to the enhanced resolution of the
method used. Although overall for each previously published or
Figure 1. Array CGH based identification of amplified chromosome 8p11.23-11.22 region encompassing ADAM9 gene.
doi:10.1371/journal.pone.0054705.g001
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‘‘archetypal’’ CNA for OSCC, there was a representative finding
in our study, we did observe samples that did not follow this
model. A valid and probable explanation for this finding is that
combining the enhanced resolution methodology with a large
ethnically diverse cohort results in highly heterogeneous results.
This has been also discovered for a wide variety of other cancers,
where even within the same solid tumour, in the same individual, 5
different sub-types of cancer genomes were discovered [8].
Using this technology, few well documented CNAs were
identified previously by others in OSCC that include amplification
of 8q24 (MYC and PTK2), 3q24-29 (TERC, SOX2, EPHB3),
11q13 (PPFIA1, CTTN, FGF3, FGF4, FADD, CCND1), 11q22.3
(MMP7, MMP20, MMP27, MMP8, MMP10, MMP1, MMP3,
MMP12, MMP13) and deletion of 3p26.3-p11.2 (FHIT, WNT5A)
[19,23,24,25,26,27,28,29]. Out of the common OSCC regions
reported from Ambatipudi et al. [19] study, few common CNAs
which showed high frequently amplification and deletion and their
OSCC related genes were identified: 8q24.13-q24.3 (MYC,
NDRG1, PTK2 and EXT1); 9q13-34.3 (CTSL1 and TNC);
11q23.3-q25 (ETS1); 14q21.3-q31.1 (HSP90AA1); 20q11.21-
q13.33 (BCL2L1, TGIF2, TOP1) and 4q13.2 (UGT2B17).
Through the basis of annotation suggesting that PTK2, CTTSL1,
TNC, ETS1 and HSP90AA1 were involved in tumor cell
proliferation, prevent tumor cell from apoptosis and promote
tumor cell invasion in oral carcinogenesis [30,31,32,33,34,35].
PTK2 encodes protein focal adhesion kinease which regulates cell
adhesion in extracellular matrix and promote tumor invasion in
oral carcinogenesis [31]. Activation of this gene also promotes cell
proliferation and prevent tumor cell from apoptosis in OSCC [31].
Interestingly, Nagaraj and Zacharias [36] have showed that the
stimulation of cigarette smoke would activate the proteolytic
activity of CTSL1, which will degrade the matrix and enhance
tumor cell invasion in oral carcinogenesis [33]. According to Jones
and Jones [32] revealed that TNC is encoded as an ECM protein
(tenascin-C) and the over-expression of this gene would enhance
the tumor cell proliferation and invasion in tumorigenesis. Up-
regulation of this gene has been found to correlate with tumor
invasion in OSCC samples [33]. In Dittmer [34] study reported
that over-expression of ETS1 would promote tumor invasion due
to its ability to activate the MMP1, MMP3, MMP9 and uPA as
well as of VEGF in tumorigenesis. HSP90AA1 encodes heat
related proteins and activation of the chaperone protein would
lead to cell proliferation and promote cell survival in tumorigenesis
[35].
We also observed high frequency of amplification on chromo-
some 20q11.21-q13.33 in agreement with Sparano et al. [27] and
Ambatipudi et al. [19] studies. Within this amplicon, BCL2L1,
TGIF2, TOP1 genes were reported to be associated with OSCC.
BCL2L1 plays an important role in apoptotic regulation that codes
for anti-apoptotic and pro-apoptotic splice variant [37]. This gene
was reported to be over-expressed in HPV-positive OSCC, when
compared with HPV-negative OSCC using cDNA microarray
[38]. Amplification of TGIF2 was reported to play a role in
chromosomal instability in tumorigenesis indicating that this gene
as a driver of chromosome 20q gain associated with oral
carcinogenesis [39]. TOP1 gene was reported as amplified in
colorectal cancer using fluorescent in situ hybridization (FISH)
technique [40]. However, the mechanism of this gene remains
unclear and further downstream analysis is recommended to
clarify its role in oral carcinogenesis.
Using aCGH, we identified a complex pattern of amplifications
and deletions of chromosome 4q13.2 in this study, which
contained UGT2B17 gene. This phenomenon was also observed
in Ambatipudi et al. [19] study, suggesting the tumor heteroge-
neity. UGT2B17 was reported as deleted in Jarvinen et al. [28]
study which was mainly involved with tongue and larynx SCC.
The complexity of differences in this gene reported in all these
studies might be due to the employed OSCC samples different in
term of socio-demographical and clinical such as risk habits
(smoking, betel quid chewing and drinking alcohol) and tumor
sites. The copy number polymorphism of this gene in cancer
warrants further research into the role of this gene in OSCC.
In this study, we found amplification of 8p to be the most
frequent event, being present in 80% (n = 37) of all OSCC
Figure 2. Array CGH based identification of amplified chromosome 7q34 region encompassing MGAM gene.
doi:10.1371/journal.pone.0054705.g002
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included here. Genomic alterations at chromosome 8p have been
frequently reported in human malignancy especially amplification
of chromosome 8p11-12, which are rich with putative oncogenes
[41,42]. The entire gain of the p-arm of chromosome 8 has been
implicated in many epithelial cancers, including breast cancer
[43,44]. This location is associated with several ADAMs family
genes including ADAM9, ADAM5P, and ADAM32. ADAM
family genes are generally transmembrane proteins, where its
activation can lead to cell adhesion, proliferation, migration and
proteolysis in cancer progression [19,45]. The expression of
ADAMs family gene has been identified with high-risk oral
premalignant lesions, whereby it suggests the possibility of a role of
these genes in OSCC transformation [46]. Another study by
Sircoulomb et al. [47] has identified that amplification of 8p11.23
resulted in over-expression of the ERBB2 gene (an oncogenic
tyrosine kinase) in estrogen receptor positive breast cancer.
Interestingly, a recent study using SNP array, on small cell lung
cancer cell line, SCLC-21H, showed massively amplified segments
of chromosome 8 that suggested this abnormality to be attributed
to a mechanism termed chromothripsis, a phenomenon char-
acterised by tens to hundreds of genomic rearrangements which
take place in a ‘one off’ cellular crisis. It was suggested and showed
by fluorescent in situ hybridization (FISH) karyotyping method
that a possible mechanism for this, is that in the development of
cancer, chromosome 8 is fragmented into pieces which are then
stitched together into a derivative chromosome 8. The remaining
fragments which are not stitched together would join to form a
double minute chromosome. As this double minute chromosome
contain genes such as MYC which would confer selective
advantage to the daughter cells to multiply, additional internal
rearrangements and over-replication, would result in the evolve-
ment of massive amplification of chromosome 8 [48]. It is
plausible that frequent amplification of 8 p as shown in this study
might be due to this mechanism. Alternatively, as the entire p-arm
is amplified, repeat elements at the centromere and p-telomere of
chromosome 8 may be mediating its amplification by homologous
recombination.
In this study cohort, high recurrent deletion of chromosome
3q26.1 was observed. Loss of 3q26.1 was observed in Familial
Adenomatous Polyposis (FAP), an autosomal dominantly inherited
form of colorectal cancer (CRC). In a study to identify a new
cancer gene using genome-wide genotyping on mutation negative
adenomatous polyposis coli (APC) gene in Familial adenomatous
polyposis (FAP) family which was matched to on ethnicity and
healthy controls, a CNA region at 3q26.1 was shown to be
commonly lost in all polyps and was suggested to be precursors to
CRC. This region was suggested to contain an element which is
involved in the expression of an upstream tumor suppressor,
PPM1L (protein phosphatase, Mg2+/Mn2+ dependent-like).
PPM1L was quite recently discovered and characterised as a
coding for a novel serine-threonine phosphatase in the oncogenic
TGF-beta and BMP signalling pathways [49].
On chromosome 1q21.3-q22, a 3.5 Mb amplification contained
more than 100 genes. These regions were reported to harbour
Figure 3. The ideogram of top most frequently CNAs in term of amplifcations and deletions identified in this study using aCGH.
doi:10.1371/journal.pone.0054705.g003
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potential oncogenes such as HAX-1, MUC1 and CKS1B genes,
which have been previously reported as being amplified and over-
expressed in OSCC samples [50,51,52]. HAX-1 is a HS1
associated protein X-1 which is reported to play an important
role in protecting tumor cell from apoptosis and promote
metastasis in breast cancer [53]. The over-expression of HAX-1
in OSCC is reported to promote tumor cell invasion by binding
directly to beta6 and regulate the clathrin-mediated endocytosis of
alphavbeta6 integrins in oral carcinogenesis [50]. MUC1 encodes
a transmembrane glycoprotein that promotes the invasion of
tumor cell and metastasis in tumorigenesis. Tsui and Garnis [54],
reported, a complex pattern of amplification and deletion of this
gene in tongue SCC cell lines using array CGH. Similarly, MUC1
was reported to be amplified and up regulated in advanced OSCC
in an integrative study between copy number and gene expression
of OSCC microarray data presented by Xu et al. [55]. The
oncogenic function of MUC1 has been well reported in various
cancers [56]. Recently, this gene has been suggested as an
indicator for neck dissection for OSCC patients that were
predicted to have lymph node metastasis [52]. CKS1B has been
reported as an amplified gene in OSCC samples and over-
expression of this gene could lead to the uncontrollable cell
proliferation through dysregulation of the cyclin-dependent
kinases (CDKs) in cell cycle progression in oral carcinogenesis
[51].
We observed high amplification of chromosome 11q11 and
2p22.3 in the current study. Amplification of 11q11 contained
olfactory receptors genes (OR4P1P, OR4S2, OR4C11, OR4C6
and OR4P4) and this region was reported to be amplified in
OSCC samples [57]. Surprisingly, this region was reported
amplified and deleted in different OSCC samples [19]. This
suggested the possibility of copy number polymorphism of this
region in OSCC genome. Similarly, amplification of chromosome
2p22.3 was identified in genome wide association study with oral
cancer patients that were highly exposed to chewing tobacco [58].
This implies chewing tobacco could lead to CNA amplification in
this region and lead to OSCC.
On chromosome 6p21.32, HLA-DRB5, HLA-DQB1 and
HLA-DQA1 were identified as amplified in OSCC genome using
aCGH. In Ambatipudi et al. [19] study, this region was reported
amplified and deleted in among the OSCC samples differently by
using the lower resolution oligonucleotide aCGH. However,
Jarvinen et al. [28] reported that this region was deleted in the
tongue SCC samples by using the lower resolution and sensitivity
of BAC aCGH. This might implicate the existence of tumor
heterogeneity and the possibility of contamination with normal
and stromal cells in the tumor tissues that were tested in this study.
CNAs that identified from aCGH were further validated using
qPCR method. In this study, qPCR copy number analysis on
ADAM5P gene was carried out and more than 80% of the OSCC
samples involved in aCGH (n = 46 OSCC) and qPCR (n = 48)
Figure 4. Amplification of ADAM5P, MGAM and SIRPB1 identifed by using aCGH and qPCR in OSCC samples. The percentage for
amplification of ADAM5P were almost similar from aCGH and qPCR study with 80% (37/46 OSCC samples) and 81.25% (39/48 OSCC samples),
respectively. Similarly, the percentage of the amplification detected from aCGH and qPCR for MGAM gene were also reported as 74% (37/46 OSCC
samples) and 50% (24/48 OSCC samples), respectively. The percentage of amplification identified from aCGH and qPCR for SIRPB1 were 61% (28/
46 OSCC samples) and 25% (12/48 OSCC samples).
doi:10.1371/journal.pone.0054705.g004
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showed amplified. Previously, ADAM5P have been reported as
deleted in OSCC genome using the low resolution array CGH
[19,28]. The amplification of ADAM5P in more than 50% of the
OSCC samples both in aCGH and qPCR further supported the
evidence of tumor heterogeneity in OSCC. ADAM5P as the name
implies is a pseudogene, which is located at chromosome 8p11.21.
Only little is known about the possible role of pseudogenes in
contributing tumorigenesis. However, study by Hirotsune et al.
[59] has shown that pseudogene could regulate the expression of
the gene by disrupting the transcription of the protein with an
unclear mechanism.
The present study has identified a novel genomic amplification
on chromosome 7q34 which was present in 34 out of 46 OSCC
samples. Validation using qPCR showed that only 50% of the
OSCC samples (n = 48) with MGAM copy number gain
(2.2560.18 copy numbers). This might be due to the dissimilarity
between the array CGH platform and the qPCR based copy
number assays as well as the differences is the intra-genic copy
number variations of this gene [60]. There was no deletion
identified for MGAM gene throughout the OSCC samples, using
aCGH in our study. However, qPCR result showed more than
50% of the OSCC samples with low copy number gains (2.0–2.5
copy number). This could be due to the limitation of oligonucle-
otide platform of aCGH with its inability to identify the low-level
copy number gains and deletions from the genome from the test
samples [61]. The low copy number of gains detected from qPCR
also might be due to the designation of qPCR assays that span the
coding sequence of the candidate genes, while the aCGH probes
span both coding and non-coding sequences [60].
In the present study, we observed a complex pattern of
amplification (28/46) and deletion (14/46) of chromosome
20p13.1 using aCGH in correspondence to the SIRPB1 gene in
different OSCC samples. The amplification and deletion of this
gene have been reported in osteosarcoma, adenocarcinoma and
chronic myeloid leukemia [62]. This can be explained by the copy
number polymorphic characteristic of this gene [63]. These
findings also showed the existence of tumor heterogeneity in tumor
tissue. Validation using qPCR on this gene showed only 25% of
the OSCC samples (n = 46) with amplification. The remaining
samples were not determined, which suggested the homozygous
deletion by this technique. Although the percentages to detect
amplification of this gene in OSCC samples were small, it might
suggest that the ultra-dense array CGH is more sensitive to detect
the copy number alterations throughout the genome level.
Recently, this technology has been introduced as a diagnostic
tool for cancer and genetic disease. Another possible explanation
might be due to the designation of qPCR assays that span the
coding sequence of the SIBPB1 genes while the aCGH probes
span both coding and non-coding sequences [60]. Ambatipudi
et al. [19] has also revealed SIRPB1 in their genome wide
profiling among Indian populations who were highly exposed to
betel quid chewing. Genetic alteration of this gene has also been
found in primary myelofibrosis [62] and colon cancer [64].
SIRPB1 is a member of the signal-regulatory protein (SIRP) family
and the activation of this gene is involved in activating the SYK-
JAK-STAT signalling, that regulates the proliferation and survival
of cancer cells in tumor progression [62]. In view of this, the
occurrence of this particular gene with oral cancers reflects the
Figure 5. The gene expression level (RQ) of MGAM and ADAM9 in OSCC samples. The gene expression level (RQ) of MGAM and ADAM9 in
OSCC samples based on the fold change which expressed as an average of 30 OSCC samples. In OSCC, MGAM has the highest gene expression level
(RQ= 6.6) where the gene expression between OSCC and normal mucosa is statistically significant (p = 0.001). This is followed by ADAM9 with gene
expression level of RQ= 1.51 (p = 0.093). The RQ for normal tissue (NT) of the two genes were 1 due to the normalization.
doi:10.1371/journal.pone.0054705.g005
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need for further studies on SIRPB1 genes to understand their role
in oral cancer progression.
In this study, there is the lack of significant correlation
association between the CNAs with socio-demographical and
clinico-parameters which may be due to the limited power of the
number of samples employed in this study. A larger set of OSCC
samples are needed to yield significant CNAs that are associated
with clinical outcomes. This is due to the fact that OSCC could be
derived from different subsites within the oral cavity and form
heterogeneous groups. Each of them behaved differently in clinical
aspects and may have a different pattern of chromosomal
aberrations.
It is well established that genomic amplification at gene(s) loci
can increase gene dosage, which can lead to over-expression at
mRNA level [65]. To characterise this, mRNA expression of
ADAM9 and MGAM was quantified in 30 OSCCs. This
comprised 19 samples involved in aCGH study and another
independent set of 11 OSCC samples. These genes were chosen
due to their high amplification frequency and also on the basis of
their gene annotation, suggesting their likely involvement in
tumorigenesis [21,22]. ADAM9 has been previously implicated as
a potential oncogene and therapeutic target for various cancers
[21,66] whilst MGAM gene has been reported to be amplified in
gastric cancer genomes [22].
This study has identified a novel genomic amplification on
chromosome 7q34 which was present in 34 out of 46 OSCC
samples. The MGAM gene at this locus was significantly over
expressed (6.6 fold) in 29 out of 30 samples analysed. It has been
previously suggested that MGAM is a carbohydrate active enzyme
that is involved in cell metabolism by breaking down the dietary
starches and sugars into glucose [67]. The involvement of this gene
in carcinogenesis could be explained by the Warburg effect which
implies that during tumor progression, alterations are observed in
glucose metabolism including glycolysis and oxidative phosphor-
ylation process in cancer cells [68]. It could be hypothesized that
over expression of MGAM may promote tumor growth by altering
cell metabolism. Further investigation of this gene is required to
elucidate its function, regulation and role in oral carcinogenesis.
In this study, ADAM9 gene was present on a genomic locus that
was amplified on chromosome 8p11.23-11.22 whereas in the
mRNA expression study, 76.67% (n = 23/30) OSCCs showed
over expression of ADAM9 while the remaining OSCCs showed
under-expression of this gene. Although the over-expression of
ADAM9 was not at a significant level, the amplification of
chromosome 8p was identified in 36/46 (80%) of OSCC samples.
However, this finding was in contrast to the study conducted by
Ambatipudi et al. [19] where they showed that ADAM9 was
deleted in OSCC. This contradictory result could be due to the
intra- and inter-tumor heterogeneity. Li et al. [69] hypothesized
that these heterogeneities could give rise to different findings of
gene expression and copy number alterations depending on the
tumor sub-type. Interestingly despite the amplification, the gene
itself did not appear to be up-regulated in all the OSCC samples
when examined by RT-qPCR. This amplified gene could be
silenced by other regulatory mechanisms such as epigenetics that
could alter transcription into mRNA.
It is interesting to note the striking contrast between ADAM9
and MGAM. The former gene is located on a genomic
amplification which spans the entire length of chromosome 8 p,
hence likely to be driven by repeat elements at 8 p telomere and
centromere, but does not have a significant impact on elevated
expression of ADAM9 (less than 2 fold). MGAM on the other
hand is located on a very precise, almost gene-specific genomic
amplification on 7q34, and notably, is significantly over-expressed
(more than 6 fold). Combining the finding of the precision,
incidence (correlating to selective retention pressure of the CNA)
and increase gene expression, MGAM could be a significant gene
that drive OSCC development.
Supporting Information
File S1 Detailed list of candidate genes for the top most
CNAs.
(XLSX)
Acknowledgments
The authors acknowledged the Oral Cancer Research and Coordinating
Centre (OCRCC), University of Malaya (UM) for providing tissue and
data from the Malaysian Oral Cancer Database & Tissue Bank System
(MOCDTBS). The authors also acknowledged Oxford Gene Technology
for their technical support. We also thank the clinicians and pathologists
from Ministry of Health Malaysia for their expertise.
Author Contributions
Conceived and designed the experiments: VKV-C SCC Y-HY AA RBZ.
Performed the experiments: VKV-C. Analyzed the data: VKV-C AA
LPK-N Y-HY NSBMR NABMM. Contributed reagents/materials/
analysis tools: VKV-C PJP ZAAR SMI ZMZ NP TGK AR WMWM
MTA KKT. Wrote the paper: VKV-C. Proofread the manuscript: VKV-C
PJP LPK-N AA SCC RBZ. Reviewed the manuscript: VKV-C AA LPK-N
SCC Y-HY PJP ZAAR SMI ZMZ NP TGK AR WMWM MTA KKT
NSBMR NABMM RBZ.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55: 74–108.
2. Reshmi SC, Gollin SM (2005) Chromosomal instability in oral cancer cells.
J Dent Res 84: 107–117.
3. Viet CT, Schmidt BL (2010) Understanding oral cancer in the genome era.
Head Neck 32: 1246–1268.
4. Rotger M, Saumoy M, Zhang K, Flepp M, Sahli R, et al. (2007) Partial deletion
of CYP2B6 owing to unequal crossover with CYP2B7. Pharmacogenet
Genomics 17: 885–90.
5. Zhang F, Khajavi M, Connolly AM, Towne CF, Batish SD, et al. (2009) The
DNA replication FoSTeS/MMBIR mechanism can generate genomic, genic
and exonic complex rearrangements in humans. Nat Genet 41: 849–53.
6. Hastings PJ, Lupski JR, Rosenberg SM, Ira G (2009) Mechanisms of change in
gene copy number. Nat Rev Genet 10: 551–64.
7. Albertson DG, Collins C, McCormick F, Gray JW (2003) Reviews:
Chromosome aberrations in solid tumors. Nat Genet 34: 369–375.
8. Bueno R, De Rienzo A, Dong L, Gordon GJ, Hercus CF, et al. (2010) Second
generation sequencing of the mesothelioma tumor genome. PLoS One 5:
e10612.
9. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, et al. (2010)
Consensus statement: chromosomal microarray is a first-tier clinical diagnostic
test for individuals with developmental disabilities or congenital anomalies.
Am J Hum Genet 86: 749–64.
10. Miller DT, Shen Y, Wu BL (2008) Oligonucleotide microarrays for clinical
diagnosis of copy number variation. Curr Protoc Hum Genet Chapter 8: Unit
8.12.
11. Przybytkowski E, Ferrario C, Basik M (2011) The use of ultra-dense array CGH
analysis for the discovery of micro-copy number alterations and gene fusions in
the cancer genome. BMC Medical Genomics 4: 1–19.
12. Zain RB, Athirajan V, Ghani WM, Razak IA, Raja Latifah RJ, et al. (2012) An
oral cancer biobank initiative: a platform for multidisciplinary research in a
developing country. Cell Tissue Bank [In press].
13. Johnson NW (2003) Chapter 1: Global epidemiology. In: Shah JP, Johnson NW,
Batsakis JG editor. Oral Cancer. New York: Taylor & Francis Group. 3.
14. Vincent-Chong VK, Ismail S, Rahman Z, Sharifah N, Anwar A, et al. (2011)
Genome-wide analysis of oral squamous cell carcinomas revealed over
expression of ISG15, Nestin and WNT11. Oral Dis 18: 469–476.
15. Venkatraman ES, Olshen AB (2007) A Faster Circular Binary Segmentation
Algorithm for the Analysis of Array CGH Data. Bioinformatics 23: 657–663.
Genome Wide Profiling of OSCC: MGAM and ADAM9
PLOS ONE | www.plosone.org 9 February 2013 | Volume 8 | Issue 2 | e54705
16. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:
402–8.
17. Brønstad I, Wolff AS, Løva˚s K, Knappskog PM, Husebye ES (2011) Genome-
wide copy number variation (CNV) in patients with autoimmune Addison’s
disease. BMC Med Genet 12: 111.
18. Lo´pez-Nieva P, Vaquero C, Ferna´ndez-Navarro P, Gonza´lez-Sa´nchez L, Villa-
Morales M, et al. (2012) EPHA7, a new target gene for 6q deletion in T-cell
lymphoblastic lymphomas. Carcinogenesis 33: 452–8.
19. Ambatipudi S, Gerstung M, Gowda R, Pai P, Borges AM, et al. (2011) Genomic
Profiling of Advanced-Stage Oral Cancers Reveals Chromosome 11q Alter-
ations as Markers of Poor Clinical Outcome. PLoS One 6: e17250.
20. Mochizuki S, Okada Y (2007) ADAMs in cancer cell proliferation and
progression. Cancer Sci 98: 621–628.
21. Kohn KW, Zeeberg BR, Reinhold WC, Sunshine M, Luna A, et al. (2012) Gene
Expression Profiles of the NCI-60 Human Tumor Cell Lines Define Molecular
Interaction Networks Governing Cell Migration Processes. PLoS One 7:
e35716.
22. Yang S (2007) Gene amplifications at chromosome 7 of the human gastric
cancer genome. Int J Mol Med 20: 225–231.
23. Garnis C, Campbell J, Zhang L, Rosin MP, Lam WL (2004) OCGR array: an
oral cancer genomic regional array for comparative genomic hybridization
analysis. Oral Oncol 40: 511–9.
24. Baldwin C, Garnis C, Zhang L, Rosin MP, Lam WL (2005) Multiple
microalterations detected at high frequency in oral cancer. Cancer Res 65:
7561–7.
25. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, et al. (2005) Rare
amplicons implicate frequent deregulation of cell fate specification pathways in
oral squamous cell carcinoma. Oncogene 24: 4232–42.
26. Liu CJ, Lin SC, Chen YJ, Chang KM, Chang KW (2006) Array-comparative
genomic hybridization to detect genomewide changes in microdissected primary
and metastatic oral squamous cell carcinomas. Mol Carcinog 45: 721–31.
27. Sparano A, Quesnelle KM, Kumar MS, Wang Y, Sylvester AJ, et al. (2006)
Genome-wide profiling of oral squamous cell carcinoma by array-based
comparative genomic hybridization. Laryngoscope 116: 735–41.
28. Ja¨rvinen AK, Autio R, Kilpinen S, Saarela M, Leivo I, et al. (2008) High-
resolution copy number and gene expression microarray analyses of head and
neck squamous cell carcinoma cell lines of tongue and larynx. Genes
Chromosomes Cancer 47: 500–509.
29. Freier K, Knoepfle K, Flechtenmacher C, Pungs S, Devens F, et al. (2010)
Recurrent copy number gain of transcription factor SOX2 and corresponding
high protein expression in oral squamous cell carcinoma. Genes Chromosomes
Cancer 49: 9–16.
30. Roymans D, Slegers H (2001) Phosphatidylinositol 3-kinases in tumor
progression. Eur. J. Biochem 268: 487–498.
31. Kornberg LJ (1998) Focal adhesion kinase and its potential involvement in
tumor invasion and metastasis. Head Neck 20: 745–52.
32. Jones FS, Jones PL (2000) Review: The tenascin family of ECM glycoproteins:
structure, function, and regulation during embryonic development and tissue
remodeling. Dev Dyn 218: 235–59.
33. Choi P, Jordan CD, Mendez E, Houck J, Yueh B, et al. (2008) Examination of
oral cancer biomarkers by tissue microarray analysis. Arch Otolaryngol Head
Neck Surg 134: 539–46.
34. Dittmer J (2003) The biology of the Ets1 proto-oncogene. Mol Cancer 2: 29.
35. Chu SH, Liu YW, Zhang L, Liu B, Li L, et al. (2012) Regulation of survival and
chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Mol Biol Rep.
(In press).
36. Nagaraj NS, Zacharias W (2007) Cigarette smoke condensate increases
cathepsin-mediated invasiveness of oral carcinoma cells. Toxicol Lett 170:
134–45.
37. Hossini AM, Eberle J (2008) Apoptosis induction by Bcl-2 proteins independent
of the BH3 domain. Biochem Pharmacol 76: 1612–1619.
38. Lohavanichbutr P, Houck J, Fan W, Yueh B, Mendez E, et al. (2009)
Genomewide gene expression profiles of HPV-positive and HPV-negative
oropharyngeal cancer: potential implications for treatment choices. Arch
Otolaryngol Head Neck Surg 135: 180–8.
39. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of
chromosomal instability inferred from gene expression profiles predicts clinical
outcome in multiple human cancers. Nat Genet 38: 1043–8.
40. Rømer MU, Nyga˚rd SB, Christensen IJ, Nielsen SL, Nielsen KV, et al. (2012)
Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer
patients and its relation to prognosis. Mol Oncol. (In press).
41. Birnbaum D, Ade´laı¨de J, Popovici C, Charafe-Jauffret E, Mozziconacci MJ, et
al. (2003) Chromosome arm 8p and cancer: a fragile hypothesis. Lancet Oncol 4:
639–642.
42. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, et al. (2005)
Comprehensive profiling of 8p11–12 amplification in breast cancer. Mol Cancer
Res 3: 655–667.
43. Naylor TL, Greshock J, Wang Y, Colligon T, Yu QC, et al. (2005) High
resolution genomic analysis of sporadic breast cancer using array-based
comparative genomic hybridization. Breast Cancer Res 7: R1186–98.
44. Cooke SL, Pole JC, Chin SF, Ellis IO, Caldas C, et al. (2008) High-resolution
array CGH clarifies events occurring on 8p in carcinogenesis. BMC Cancer 7:
288.
45. Duffy MJ, Mullooly M, O’Donovan N, Sukor S, Crown J, et al. (2011) The
ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
Clin Proteomics 8: 9.
46. Tsui IF, Poh CF, Garnis C, Rosin MP, Zhang L, et al. (2009) Multiple pathways
in the FGF signaling network are frequently deregulated by gene amplification in
oral dysplasias. Int J Cancer 125: 2219–2228.
47. Sircoulomb F, Bekhouche I, Finetti P, Ade´laı¨de J, Ben Hamida A, et al. (2010)
Genome profiling of ERBB2-amplified breast cancers. BMC Cancer 10: 539.
48. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, et al. (2011) Massive
genomic rearrangement acquired in a single catastrophic event during cancer
development. Cell 144: 27–40.
49. Thean LF, Loi C, Ho KS, Koh PK, Eu KW, et al. (2010) Genome-wide scan
identifies a copy number variable region at 3q26 that regulates PPM1L in APC
mutation-negative familial colorectal cancer patients. Genes Chromosomes
Cancer 49: 99–106.
50. Ramsay AG, Keppler MD, Jazayeri M, Thomas GJ, Parsons M, et al. (2007)
HS1-associated protein X-1 regulates carcinoma cell migration and invasion via
clathrin-mediated endocytosis of integrin alphavbeta6. Cancer Res 67: 5275–84.
51. Martı´n-Ezquerra G, Salgado R, Toll A, Baro´ T, Mojal S, et al. (2011) CDC28
protein kinase regulatory subunit 1B (CKS1B) expression and genetic status
analysis in oral squamous cell carcinoma. Histol Histopathol 26: 71–7.
52. Hamada T, Nomura M, Kamikawa Y, Yamada N, Batra SK, et al. (2012) DF3
epitope expression on MUC1 mucin is associated with tumor aggressiveness,
subsequent lymph node metastasis, and poor prognosis in patients with oral
squamous cell carcinoma. Cancer (In press).
53. Trebinska A, Rembiszewska A, Ciosek K, Ptaszynski K, Rowinski S, et al.
(2010). HAX-1 overexpression, splicing and cellular localization in tumors. BMC
Cancer 10: 76.
54. Tsui IF, Garnis C (2010) Integrative molecular characterization of head and
neck cancer cell model genomes. Head Neck 32: 1143–60.
55. Xu C, Liu Y, Wang P, Fan W, Rue TC, et al. (2010) Integrative analysis of DNA
copy number and gene expression in metastatic oral squamous cell carcinoma
identifies genes associated with poor survival. Mol Cancer 9: 143.
56. Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev
Cancer 9: 874–85.
57. Peng CH, Liao CT, Peng SC, Chen YJ, Cheng AJ, et al. (2011) A novel
molecular signature identified by systems genetics approach predicts prognosis in
oral squamous cell carcinoma. PLoS One 6: e23452.
58. Bhatnagar R, Dabholkar J, Saranath D (2012) Genome-wide disease association
study in chewing tobacco associated oral cancers. Oral Oncol 48: 831–5.
59. Hirotsune S, Yoshida N, Chen A, Garrett L, Sugiyama F, et al. (2003) An
expressed pseudogene regulates the messenger-RNA stability of its homologous
coding gene. Nature 423: 91–6.
60. Sriram KB, Larsen JE, Savarimuthu Francis SM, Wright CM, Clarke BE, et al.
(2012) Array-comparative genomic hybridization reveals loss of SOCS6 is
associated with poor prognosis in primary lung squamous cell carcinoma. PLoS
One 7: e30398.
61. Tan DS, Lambros MB, Natrajan R, Reis-Filho JS (2007) Getting it right:
designing microarray (and not ‘microawry’) comparative genomic hybridization
studies for cancer research. Lab Invest 87: 737–54.
62. Visani G, Sapienza MR, Isidori A, Tripodo C, Laginestra MA, et al. (2011)
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in
primary myelofibrosis. PLoS One 6: e27560.
63. Flossbach L, Holzmann K, Mattfeldt T, Buck M, Lanz K, et al. (2012) High-
resolution genomic profiling reveals clonal evolution and competition in
gastrointestinal marginal zone B-cell lymphoma and its large cell variant.
Int J Cancer (In press).
64. Camps J, Grade M, Nguyen QT, Ho¨rmann P, Becker S, et al. (2008)
Chromosomal breakpoints in primary colon cancer cluster at sites of structural
variants in the genome. Cancer Res 68: 1284–95.
65. Albertson DG (2006) Gene amplification in cancer. Trends Genet 22: 447–455.
66. Fry JL, Toker A (2010) Secreted and membrane-bound isoforms of protease
ADAM9 have opposing effects on breast cancer cell migration. Cancer Res 70:
8187–8198.
67. Sim L, Willemsma C, Mohan S, Naim HY, Pinto BM, et al. (2010) Structural
basis for substrate selectivity in human maltase-glucoamylase and sucrase-
isomaltase N-terminal domains. J Biol Chem 285: 17763–17770.
68. Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window
opens. Nat Rev Drug Discov 10: 671–684.
69. Li J, Wang K, Jensen TD, Li S, Bolund L, et al. (2010) Tumor heterogeneity in
neoplasms of breast, colon, and skin. BMC Research Notes 3: 321.
Genome Wide Profiling of OSCC: MGAM and ADAM9
PLOS ONE | www.plosone.org 10 February 2013 | Volume 8 | Issue 2 | e54705
